GW-501516

History

GW-501516 was developed through pharmaceutical research investigating selective activation of PPARδ, a nuclear receptor involved in lipid metabolism, glucose homeostasis, and energy utilization. Early preclinical research demonstrated that PPARδ activation could modify skeletal-muscle metabolic pathways and increase oxidative metabolism. Subsequent animal studies attracted significant interest because of reported changes in endurance-related metabolic characteristics. Clinical research later investigated GW-501516 for metabolic and cardiovascular indications, including dyslipidemia and metabolic risk factors. Development was ultimately discontinued, and the compound did not progress to an approved therapeutic medicine. (pubmed.ncbi.nlm.nih.gov

NEXON

Chemical Structure

GW-501516 is a non-hormonal small molecule that acts primarily as a selective agonist of PPARδ.

Its mechanism differs fundamentally from anabolic steroids and SARMs because its primary target is a nuclear receptor involved in metabolic gene regulation rather than the androgen receptor.

NEXON

Pharmacology

GW-501516 selectively activates PPARδ, a nuclear receptor expressed in tissues including skeletal muscle, adipose tissue, liver, and other metabolically active organs.

• Activation of PPARδ influences transcription of genes involved in:
• Fatty-acid oxidation
• Energy metabolism
• Lipid transport
• Glucose utilization
• Mitochondrial oxidative metabolism

This mechanism distinguishes Cardarine from anabolic-androgenic steroids and SARMs.

NEXON

Mechanism of Action

The principal mechanism involves activation of PPARδ.

• The general pathway includes:
• Oral absorption
• Systemic distribution
• Binding to PPARδ
• Nuclear receptor activation
• Formation of receptor complexes
• Interaction with regulatory DNA sequences
• Regulation of metabolic gene transcription
• Modulation of lipid and energy metabolism

NEXON

Pharmacodynamics

GW-501516 influences metabolic physiology primarily through PPARδ-mediated gene regulation.

NEXON

Physiological Effects

GW-501516 primarily influences physiological function through activation of PPARδ, a nuclear receptor involved in lipid utilization and energy metabolism. Activation of this pathway can increase the expression of genes associated with fatty- acid oxidation, mitochondrial oxidative activity, and metabolic energy utilization. In preclinical models, these effects have been associated with a shift toward greater oxidative metabolism in skeletal muscle and improved metabolic handling of fatty acids.

Cardarine does not directly function as an anabolic steroid, SARM, or growth hormone secretagogue. Its physiological GW-501516 profile is ancentered is instead orally active small molecule on metabolic that undergoes regulation, particularlygastrointestinal absorption pathways involving and systemic lipid metabolism, distribution. glucose utilization, and energy expenditure. However, the potential benefits observed in experimental models should not be interpreted as Human pharmacokinetic established clinical effectsstudies have in humans, anddemonstrated its long-term measurable safety remains systemic a major exposure concern. following oral administration. The compound undergoes hepatic metabolism and produces circulating metabolites that can be detected analytically.

Because GW-501516 is not an approved therapeutic medication, pharmacokinetic parameters should be interpreted according to the specific research formulation and study population. NEXON

Clinical Applications

GW-501516 was investigated experimentally for metabolic and cardiovascular conditions in which modulation of PPARδ could potentially provide therapeutic benefits.

• Research areas included:
• Dyslipidemia
• Metabolic disorders
• Lipid metabolism
• Cardiovascular risk factors
• Glucose metabolism

Clinical development was discontinued, and GW-501516 has not been approved as a treatment for these conditions.

NEXON

Safety Considerations

The use of anabolic-androgenic steroids may require consideration of cardiovascular, hematological, hepatic, endocrine, metabolic, and reproductive health.

Important safety considerations include:

• Cardiovascular health
• Blood pressure
• Hematological parameters
• Lipid profile
• Liver function
• Endocrine function
• Reproductive function
• Prostate health

The overall safety profile depends on the specific compound, formulation, concentration, duration of exposure, individual response, and patient characteristics. Appropriate medical evaluation and regular monitoring should be considered when clinically indicated.

NEXON

Potential Adverse Effects

Potential adverse effects associated with anabolic-androgenic steroid exposure may involve endocrine, cardiovascular, hematological, hepatic, dermatological, reproductive, and metabolic systems.

• Endocrine Effects
• Suppression of endogenous hormone production
• Alterations in hormonal balance
• Changes in reproductive hormone signaling
• Potential suppression of spermatogenesis

• Cardiovascular Effects
• Changes in lipid profile
• Possible increases in blood pressure
• Potential cardiovascular risk

• Hematological Effects
• Changes in hematocrit
• Changes in hemoglobin
• Possible increase in erythropoietic activity

• Dermatological Effects
• Acne
• Increased sebaceous activity
• Androgen-related hair loss in genetically predisposed individuals

• Reproductive Effects
• Changes in reproductive function
• Potential reduction in fertility
• Alterations in reproductive hormone regulation

• Hepatic & Metabolic Effects
• Changes in liver function parameters
• Alterations in metabolic markers
• Changes in glucose and lipid metabolism

The occurrence and severity of adverse effects vary according to the specific compound, formulation, exposure, duration of use, individual response, and patient characteristics.

NEXON

Contraindications

Condition Reason Severe hepatic disease Increased hepatic risk Hormone-sensitive cancers Androgen receptor sensitivity Pregnancy Potential risk of fetal development Known hypersensitivity Allergic reaction Significant cardiovascular disease Potential cardiovascular effects

NEXON

Drug Interactions

A comprehensive interaction profile may not be established for every anabolic-androgenic steroid or formulation.

• Potential interactions or clinical considerations may exist with:
• Anticoagulants
• Antidiabetic medications
• Hepatotoxic medications
• Other anabolic-androgenic steroids
• Other hormonal therapies
• Drugs affecting lipid metabolism

The clinical significance of potential interactions depends on the specific compound, formulation, dosage, duration of exposure, concomitant medications, and individual patient characteristics. Appropriate medical evaluation should be considered when multiple medications or hormonal therapies are used concurrently.

NEXON

Laboratory Monitoring

Laboratory Test Purpose CBC Monitor hematological parameters

ALT / AST Liver function

Bilirubin Hepatic assessment

Lipid Profile Cardiovascular risk assessment

Blood Pressure Cardiovascular monitoring

Total Testosterone Assess androgen status

LH / FSH Assess endocrine suppression

NEXON

Storage & Stability

• Store according to official product labeling.
• Protect from excessive heat and direct sunlight.
• Do not freeze.
• Maintain original packaging integrity.
• Keep away from children.
• Inspect packaging before use.

NEXON

Product Authenticity

Every genuine NEXON product should include appropriate quality verification features.

Authentication may include:

• Batch number tracking
• Manufacturing information
• Expiration date verification
• QR authentication system
• Authorized distribution verification

emphasizes transparency, traceability, and product quality control.

NEXON

Frequently Asked Questions

What is GW-501516? GW-501516, commonly known as Cardarine, is an experimental PPARδ agonist that influences metabolic pathways involving lipid and energy utilization.

Is GW-501516 a SARM? No. Cardarine is not a SARM. It primarily acts through PPARδ rather than the androgen receptor.

Is GW-501516 a steroid? No. It is a non-hormonal small-molecule metabolic modulator.

Is GW-501516 oral or injectable? GW-501516 is an orally administered compound.

Does GW-501516 increase testosterone? No. Its primary pharmacological target is PPARδ rather than the androgen receptor or testosterone-production pathway.

What is Cardarine primarily associated with? Cardarine is primarily associated with research into lipid metabolism, fatty-acid oxidation, energy utilization, and exercise- related metabolic pathways.

NEXON

Quality Commitment

is committed to maintaining high standards of manufacturing quality, product consistency, traceability, and scientific transparency.

Through quality control systems, authentication procedures, and responsible information sharing, NEXON aims to provide reliable pharmaceutical products and educational resources for healthcare professionals and informed users.

NEXON